Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study

Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study

Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve surgical resection, and prolong event-free and overall surviva...

Full description

Bibliographic Details
Main Authors: Matheus Sewastjanow-Silva, Lianchun Xiao, Graciela N. Gonzalez, Xuemei Wang, Wayne Hofstetter, Stephen Swisher, Reza Mehran, Boris Sepesi, Manoop S. Bhutani, Brian Weston, Emmanuel Coronel, Rebecca E. Waters, Jane E. Rogers, Jackie Smith, Larry Lyons, Norelle Reilly, James C. Yao, Jaffer A. Ajani, Mariela Blum Murphy
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
adenocarcinoma
atezolizumab
esophagus
gastroesophageal junction
immunotherapy
NCT03784326
Online Access:https://www.mdpi.com/2072-6694/16/7/1378

Internet

https://www.mdpi.com/2072-6694/16/7/1378

Similar Items